Axon Enterprise Inc (AXON) Q2 2025 Earnings Call Highlights: Record Revenue Growth and Raised ...
Software and Services Revenue: $292 million, grew 39% year-over-year.
Connected Devices Revenue: $376 million, increased 29% year-over-year.
TASER Revenue: Grew 19%, driven by TASER 10.
Personal Sensors Revenue: Grew 24%, driven by Axon Body 4.
Platform Solutions Revenue: Grew 86%, driven by counter-drone and virtual reality.
Net Revenue Retention: Increased to 124%.
Adjusted Gross Margin: 63.3%, up 20 basis points year-over-year.
Adjusted EBITDA Margin: 25.7%.
2025 Revenue Guidance: Raised to $2.65 billion to $2.73 billion, approximately 29% annual growth at the midpoint.
Adjusted EBITDA Guidance: Raised to $665 million to $685 million.
Warning! GuruFocus has detected 8 Warning Sign with AXON.
Release Date: August 04, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
Axon Enterprise Inc (NASDAQ:AXON) reported a 33% year-over-year increase in second-quarter revenue, marking its 14th consecutive quarter of over 25% revenue growth.
The company experienced strong growth in its Software and Services segment, which grew 39% year-over-year to $292 million.
Axon Enterprise Inc (NASDAQ:AXON) raised its 2025 revenue guidance to a range of $2.65 billion to $2.73 billion, reflecting approximately 29% annual growth at the midpoint.
The company closed almost $150 million of bookings for its AI Era Plan in Q2 alone, with over 30% of bookings this quarter coming from new product categories.
Axon Enterprise Inc (NASDAQ:AXON) achieved its largest deal in company history with a major city police department, encompassing a wide range of products from drones to AI solutions.
Negative Points
Despite strong growth, the company faces challenges with tariffs, which are expected to impact financials more in the second half of the year.
The deployment of enterprise solutions is complex and presents challenges, as it involves aggregating large amounts of video data.
The company anticipates lumpiness in its Platform Solutions segment due to the nature of large deals, particularly in counter-drone technology.
Axon Enterprise Inc (NASDAQ:AXON) is still in the early stages of monetizing its drone technology, with current revenue primarily coming from software rather than hardware.
The company acknowledges the need for continued investment in R&D and sales to maintain its growth trajectory, which could impact short-term profitability.
Q & A Highlights
Q: Can you discuss the enterprise addressable market and which products are gaining traction? A: Enterprise is performing well with interest across a broad range of products, including Body Cams, Evidence.com, Fusus, and drones. The full suite of products is gaining traction, and the largest deal in company history was booked this quarter, driven by strong execution from the product and sales teams. - Josh Isner, President
Q: Could you elaborate on the $150 million of bookings from the AI Era Plan in Q2? A: The AI Era Plan is accelerating, with significant demand for Draft One and other AI products like AI Assistant and real-time translator. The plan is well-received due to the time savings and practical applications it offers to customers. - Josh Isner, President
Q: What underpinned the success of Platform Solutions, particularly in counter-drone technology? A: The success is driven by increased awareness of drone threats, as seen in global conflicts. Our acquisition of Dedrone positions us as a market leader in counter-drone solutions, with growing demand across various sectors. - Patrick Smith, CEO
Q: What is driving the high 30% bookings growth guidance, and how does the pipeline look? A: The growth is driven by selling new products to existing customers and expanding into new markets like international and enterprise. The diversified product portfolio and strong pipeline give us confidence in achieving the growth target. - Josh Isner, President
Q: How are AI bookings progressing, and what lessons have been learned in overcoming hurdles? A: AI bookings are progressing well, with hands-on product trials proving effective in demonstrating value. Products like Draft One and AI Assist are helping officers spend more time in the field, and the focus remains on practical applications that enhance public safety. - Josh Isner, President
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
Philip Morris Stock Outlook: Is Wall Street Bullish or Bearish?
With a market cap of $253.7 billion, Philip Morris International Inc. (PM) is a global tobacco company focused on delivering a smoke-free future. Its product portfolio includes traditional cigarettes, smoke-free alternatives like IQOS and ZYN, and expanding offerings in wellness and healthcare. Shares of the Stamford, Connecticut-based company have outperformed the broader market over the past 52 weeks. PM stock has surged 38.3% over this time frame, while the broader S&P 500 Index ($SPX) has gained 18.4%. Moreover, shares of Philip Morris are up 35.4% on a YTD basis, compared to SPX's 7.6% increase. More News from Barchart Dear Nvidia Stock Fans, Mark Your Calendars for August 27 Options Traders Expected Palantir Stock's Tamest Earnings Reaction in a Year. Did They Get It Right? Tesla Gains on Elon Musk's New Pay Package. Is TSLA Stock a Buy? Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. Narrowing the focus, the tobacco giant stock has also outpaced the Consumer Staples Select Sector SPDR Fund's (XLP) 1.6% rise over the past 52 weeks. Despite reporting a better-than-expected Q2 2025 adjusted EPS of $1.91, shares of Philip Morris tumbled 8.4% on Jul. 22. Total sales rose 7.1% to $10.1 billion and ZYN shipments came in at 190 million cans, both missing analysts' estimates. For the fiscal year ending in December 2025, analysts expect PM's adjusted EPS to grow 14.3% year-over-year to $7.51. The company's earnings surprise history is promising. It beat the consensus estimates in the last four quarters. Among the 14 analysts covering the stock, the consensus rating is a 'Strong Buy.' That's based on nine 'Strong Buy' ratings, two 'Moderate Buys,' and three 'Holds.' On Jul. 14, UBS maintained its 'Neutral' rating on Philip Morris but raised its price target to $181, citing strong smoke-free margin growth driven by IQOS and ZYN, with robust U.S. volume projections and revised earnings estimates through 2027. As of writing, the stock is trading below the mean price target of $193.38. The Street-high price target of $220 implies a potential upside of nearly 35% from the current price. On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 minutes ago
- Yahoo
Alcon Expands Vision Correction Portfolio With STAAR Surgical Acquisition
On Tuesday, the eye care company Alcon Plc (NYSE:ALC) agreed to acquire STAAR Surgical Company (NASDAQ:STAA), the manufacturer of the implantable collamer lens (ICL). The acquisition includes the EVO family of lenses (EVO ICL) for vision correction for patients with moderate to high myopia (nearsightedness), with or without astigmatism. Alcon will purchase all outstanding shares of STAAR common stock for $28 per share in cash, which represents approximately a 59% premium to STAAR's 90-day Volume Weighted Average Price (VWAP) and a 51% premium to the closing price of STAAR common stock on August 4, transaction represents a total equity value of approximately $1.5 billion. Alcon intends to finance the transaction by issuing short- and long-term credit facilities. The transaction is anticipated to close in approximately six to 12 months and is expected to be accretive to earnings in year two. 'With the number of high myopes rising globally, the acquisition of STAAR enhances our ability to offer a leading surgical vision correction solution for those who are not ideal candidates for other refractive surgeries such as LASIK,' said David Endicott, CEO of Alcon. An estimated 50% of the world will be myopic by 2050, and today, nearly 500 million people are considered high myopes. The EVO family of ICLs are implanted between the iris (the colored part of the eye) and the natural crystalline lens during a procedure that does not remove corneal tissue. This move follows Alcon's recent announcement in July regarding its intention to acquire LumiThera, Inc. and its Photobiomodulation (PBM) Device for dry age-related macular degeneration (AMD). Data from the LIGHTSITE I, II, and III clinical trials consistently showed that PBM treatments provide visual acuity improvement with no treatment-related serious adverse events reported. PBM received FDA de novo market authorization in November 2024 and CE Mark in November 2018. PBM is available in Europe, Latin America, Singapore, the U.K., and the U.S. The transaction does not include the acquisition of AdaptDx and Nova/Diopsys diagnostic devices, which will be separated and spun off to LumiThera's shareholders before Alcon's acquisition and will continue to be marketed and sold by the LumiThera spin-off. Alcon and LumiThera anticipate the acquisition to be completed in the third quarter of 2025. Price Action: ALC stock is trading lower by 1.17% to $86.79 premarket, and STAA stock is trading higher by 44.9% to $26.78 at last check Tuesday. Read Next:Photo via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? STAAR SURGICAL (STAA): Free Stock Analysis Report This article Alcon Expands Vision Correction Portfolio With STAAR Surgical Acquisition originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 minutes ago
- Yahoo
Caterpillar projects tariffs could cost the company up to $1.5 billion in 2025
Caterpillar's operating profit margin and sales and revenue numbers fell in the second quarter of 2025 amid ongoing uncertainty and global economic changes sparked by President Donald Trump's tariff increases. Caterpillar CFO Andrew Bonfield told investors on a call Tuesday that the net impact of tariffs on Caterpillar this year will be between $1.3 billion and $1.5 billion. The Texas-based manufacturer, which has a heavy presence in the Peoria area, posted a 1% decrease in sales and revenues in Q2 compared to this time last year and a 2.6% decrease in operating profit margin. Profits per share fell to $4.62 in the second quarter compared to $5.48 last year. Adjusted profit shares were $4.72 this quarter, down from $5.99 last year. Caterpillar CEO Joe Creed said these numbers all met or went above Caterpillar's expectations for the quarter but told investors on the call that the impact of tariffs hit the high end of Caterpillar's estimates and the impact of tariffs on their numbers was expected to grow in the second half of the year. More: Why former CEO has 'confidence' Caterpillar will be in Peoria for 'a very long time' The Trump administration has been haphazardly negotiating trade deals with nations around the globe, many of which include increases in tariff rates on goods. They have been subject to change as the administration has changed the terms and numbers of deals as negotiations progress. Creed told investors on Tuesday that Caterpillar has deployed some "initial mitigation" efforts to curb the impact of tariffs but added the company is "considering all options" as they await more "sufficient certainty" on tariffs. In response to an investor question on the call, Creed said that Caterpillar's unique global supply chain has added complexity to the situation but he said Caterpillar is still waiting on more certainty and is still working to fully understand the latest tariff announcement from the government. On July 31, Trump signed an executive order that placed reciprocal tariffs on 70 countries at rates ranging from 15% to 41%. Those tariffs are expected to go into place on Aug. 7. Caterpillar's numbers were also lower in the first quarter of 2025 as tariffs have increased costs on the global manufacturer. In April, Creed told investors on a call that he expected tariffs to have a cost headwind of between $250 million and $350 million in Q2. Bonfield said Tuesday the tariff impact in the third quarter is expected to grow to $400 million to $500 million. Roughly 20% of the tariff impact will be on resource industries and 25% will be on transportation. The decrease in sales and revenues was because of "unfavorable price realization of $414 million," Caterpillar said. Despite the negative impact of tariffs, demand remains high and backlog at Caterpillar continues to grow, signaling positive markers for Caterpillar, Creed and Bonfield told investors on Tuesday. This article originally appeared on Journal Star: Caterpillar earnings fall in second quarter amid Trump tariff hikes
